Vir (VIR) Q1 2026 Earnings Call Highlights Partnership and Clinical Progress

Vir (VIR) announced a co-development and co-commercialization deal with Astellas for VIR-5500, valued at up to $1.7 billion. The company also reported positive Phase 1 data showing a favorable safety profile and durable clinical responses in patients with advanced mCRPC. The Phase 3 trials for VIR-5500 are expected to begin in 2027.

By Motley Fool Transcribing · Motley Fool · May 6, 2026, 22:17 UTC

Vir (VIR) Q1 2026 Earnings Call Highlights Partnership and Clinical Progress

Tickers: $VIR

Topics: Astellas collaboration clinical trials Hepatitis delta pharma partnerships VIR-5500

Read the full article at Motley Fool

More World news

Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC
Nvidia, Supermicro, and Megaspeed Face U.S. Department of Justice Probes Seeking Alpha · November 12, 2026, 17:00 UTC
Starbucks Implements Quarterly Performance-Based Bonuses for Baristas Seeking Alpha · November 12, 2026, 17:03 UTC
Jim Cramer Analyzes Nvidia Leadership Transition and Recommends AMD, Constellation Brands, and Kimberly-Clark CNBC · November 12, 2026, 16:55 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Threatening $500 Billion AI Financing Plan CNBC · November 12, 2026, 16:55 UTC
Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026 PR Newswire · November 12, 2026, 17:01 UTC
SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering TechCrunch · November 12, 2026, 17:00 UTC
PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans PR Newswire · November 12, 2026, 17:00 UTC
Tesla to Discontinue Cybertruck Production by Summer 2027 to Prioritize Cybercab The Verge · November 12, 2026, 17:00 UTC
Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201 Motley Fool · November 12, 2026, 16:54 UTC